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The influenza A virus nucleoprotein (NP) is a single-stranded RNA-binding protein that encapsidates the virus
genome and has essential functions in viral-RNA synthesis. Here, we report the characterization of a temperature-
sensitive (ts) NP mutant (US3) originally generated in fowl plague virus (A/chicken/Rostock/34). Sequence analysis
revealed a single mutation, M239L, in NP, consistent with earlier mapping studies assigning the ts lesion to segment
5. Introduction of this mutation into A/PR/8/34 virus by reverse genetics produced a ts phenotype, confirming the
identity of the lesion. Despite an approximately 100-fold drop in the viral titer at the nonpermissive temperature,
the mutant US3 polypeptide supported wild-type (WT) levels of genome transcription, replication, and protein
synthesis, indicating a late-stage defect in function of the NP polypeptide. Nucleocytoplasmic trafficking of the US3
NP was also normal, and the virus actually assembled and released around sixfold more virus particles than theWT
virus, with normal viral-RNA content. However, the particle/PFU ratio of these virions was 50-fold higher than that
of WT virus, and many particles exhibited an abnormal morphology. Reverse-genetics studies in which A/PR/8/34
segment 7 was swapped with sequences from other strains of virus revealed a profound incompatibility between the
M239L mutation and the A/Udorn/72 M1 gene, suggesting that the ts mutation affects M1-NP interactions. Thus,
we have identified a late-acting defect in NP that, separate from its function in RNA synthesis, indicates a role for
the polypeptide in virion assembly, most likely involving M1 as a partner.
The influenza A virus nucleoprotein (NP) is a 56-kDa basic
RNA-binding protein encoded by segment 5 that plays an
essential structural role, encapsidating the segmented viral ge-
nome into ribonucleoproteins (RNPs). RNPs are helical struc-
tures consisting of the viral-RNA (vRNA)-dependent RNA
polymerase and a chain of NP monomers around which the
negative-sense single-stranded vRNA segments are wrapped
(56). In the early stages of the replication cycle, infecting RNPs
are imported into the nucleus, where they are transcribed and
replicated. There is much evidence that NP has essential func-
tions during this period of the viral life cycle. Nuclear local-
ization signals in the protein are sufficient to direct nuclear
import of the genome (53). Once in the nucleus, NP is essential
for vRNA synthesis (30). NP encapsidates the genome through
a sequence-independent RNA-binding activity (58, 67) and
interactions with the viral polymerase (8, 48, 55). Coating of
the genomic vRNA segments by NP is probably necessary for
synthesis of long RNA products by the viral polymerase (29),
although it is not required for the synthesis of short products
(37). NP has also long been associated with a specific require-
ment for genome replication (7, 61), although recent research
suggests this may be more as a facilitator than as a regulator
(48, 50, 65).
During the later stages of infection, RNPs traffic through the
nuclear envelope and cytoplasm to the apical plasma mem-
brane, where each of the eight individual RNP segments is
assembled into progeny virions. At present, relatively little is
known about the functions of NP during the later stages of the
replication cycle, but several studies have suggested the possi-
bility of posttranscriptional functions. The association of M1
with NP is thought to be essential for RNP nuclear export, as
the first step in forming an export complex with cellular CRM1
via NS2/NEP (9, 44). NP also interacts directly with CRM1,
although the significance of this during infection is uncertain
(1, 25). The route and mechanism by which RNPs are traf-
ficked across the cytoplasm to virion assembly sites is also
uncertain, although it has been suggested that cytoskeletal
interactions with the actin and/or tubulin networks are in-
volved (6, 19, 49, 62). NP has also been demonstrated to
associate independently with lipid rafts at the apical plasma
membrane, which may play a role in determining the polarity
of viral budding (13). Interactions between NP and M1 are also
thought to be important for the process of virion assembly
itself (38, 60, 69, 72).
Thus, NP potentially plays an important role at many steps
of the virus life cycle. However, little genetic evidence exists to
confirm the importance of biochemical data showing interac-
tions of NP with viral and cellular proteins. To remedy this, we
reexamined a series of A/chicken/Rostock/34 (formerly known
as FPV/Rostock/34; abbreviated hereafter as FPV) tempera-
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ture-sensitive (ts) mutants generated by chemical mutagenesis
in the 1970s (4, 40, 41). Characterization of the US3 mutant
did not reveal a defect in any step of vRNA synthesis, gene
expression, or NP trafficking. However, the US3 virus formed
large numbers of poorly infectious particles with defective
morphology. We conclude that this is the first direct evidence
of a role for NP in virus assembly.
MATERIALS AND METHODS
Cells, viruses, plasmids, and sequencing. Human embryonic kidney 293T and
Madin-Darby canine kidney (MDCK) cells and chicken embryo fibroblasts
(CEF) were propagated as previously described (13, 25). The Cambridge strain
of influenza virus A/PR/8/34 (c-PR8) was propagated in 10-day-old embryonated
eggs at 37°C, while wild-type (WT) (clone S3) and ts mutant FPVs were grown
at 34°C (25). PR8 virus titers were determined by plaque assay on MDCK cells,
while the titers of FPVs were determined on CEF, both according to standard
protocols (25, 62). All work with the highly pathogenic avian influenza viruses
was carried out in a Department for the Environment, Food, and Rural Affairs-
approved SAPO-4 containment laboratory at the Institute for Animal Health,
Berkshire, United Kingdom. WT and ts mutant PR8 viruses were created by
reverse genetics (see below) using the bidirectional promoter plasmid clones
described by de Wit et al. (18). The US3 mutation was introduced into segment
5 by PCR mutagenesis of the PR8 plasmid using the oligonucleotides 5-CAA
AAAGCAATGCTTGATCAAGTGAGA and 5-TCTCACTTGATCAAGCAT
TGCTTTTTG (the mutated sequence is underlined). Polymerase I reverse-
genetics plasmids containing cDNA copies of segment 7 from A/WSN/33 (WSN),
A/Udorn/72 (Udorn), or a chimera with Udorn M1 and WSN M2 were gener-
ously provided by W. Barclay (21). Plasmids pCDNA-PB1, -PB2, -PA, and -NP;
pPol-I()NS.CAT; and pPol-I()NS.CAT have been described previously (50).
To generate plasmid clones of segment 5 from WT and US3 FPV viruses, RNA
extracted from CEF incubated for 6 h at the permissive temperature (PT) of
34°C was reverse transcribed using the primer 5-CTTTAATTGTCATACT
CCTC and PCR amplified by the addition of the oligonucleotide 5-GCAGGG
TATATAATCACTCACTGAGTGACATC using Superscript II (Gibco BRL)
and Pfu (Stratagene) polymerases. The products were then A tailed by the
addition of Taq DNA polymerase (Promega) and ligated into plasmid pCRII
(Invitrogen). Sequences were determined by the DNA-sequencing facility of the
Department of Biochemistry, University of Cambridge. The NP cDNAs were
then excised from the pCRII backbone using flanking EcoRV and BamHI
restriction enzyme sites and inserted into pCDNA3.1 digested with HindIII,
followed by end filling and BamHI digestion.
Antibodies. Antisera against PR8 NP (2915), PB2 (2N580), and M1 (A2917)
and whole PR8 virus were described previously (5, 13, 52). Monoclonal antibod-
ies anti-Lap2 immunoglobulin G1 and anti-M2 14C2 were obtained from BD
Transduction Laboratories and Abcam, respectively. Horseradish peroxidase-
conjugated antibodies for Western blot analysis were supplied by GE Healthcare.
Reverse genetics. Viruses were rescued by plasmid transfection as described
previously (31), except that the cells were incubated at the PT. Virus stocks were
amplified for a maximum of two passages in MDCK cells incubated at the PT for
2 to 3 days. The presence of the US3 mutation was confirmed by directly
sequencing reverse transcription-PCR products produced from segment 5 of
each virus stock.
RNA techniques. For analysis of vRNA synthesis during infection, reverse
transcriptase primer extension reactions were performed on total cellular RNA
extracted from cells as described previously (50). The primers used to detect
positive- and negative-sense vRNAs from segments 2, 5, and 7 have been de-
scribed elsewhere (17, 50).
Protein analyses. For radioactive labeling of polypeptide synthesis, cells were
washed in methionine-free medium (MP Biomedicals) and then incubated for
2-h periods in methionine-free medium supplemented with 1.1 MBq/ml of
[35S]methionine (Amersham International, United Kingdom). The cells were
solubilized in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) sample buffer, separated by SDS-PAGE, and detected by autoradiogra-
phy or Western blotting according to standard protocols. Membrane flotation
analysis was performed as previously described (13). For immunofluorescent
detection of proteins, MDCK cells seeded onto coverslips were fixed and stained
with the appropriate antibodies as previously described (5, 13, 25). Fluorescent
emissions were imaged using an Olympus 1X70 wide-field fluorescence micro-
scope and a QImaging Retiga 2000R camera. Images were taken using QCapture
Pro 5.0 (QImaging) software and processed using Adobe Photoshop. For mini-
genome assays, influenza virus RNPs were reconstituted in 293T cells by trans-
fection of plasmids expressing the three polymerase proteins, NP, and a model
vRNA segment encoding chloramphenicol acetyltransferase (CAT) (50). CAT
accumulation was measured by enzyme-linked immunosorbent assay.
Analysis of viral particles. To generate virus stocks consisting solely of parti-
cles made at the nonpermissive temperature (NPT), confluent MDCK cells were
infected at a multiplicity of infection (MOI) of 2. After a 1-h adsorption period
at 39°C, the cells were treated with an acid wash (10 mM HCl, 150 mM NaCl, pH
3) for 1 min, washed three times in phosphate-buffered saline (PBS), and over-
laid with OptiMem (Gibco-BRL). All solutions were prewarmed to 39°C. Fol-
lowing a 24-h incubation at the NPT, the supernatant was collected. For bio-
chemical analysis of virus particles, 0.4 ml of the virus stocks made at the NPT
was diluted in an equal volume of PBS and sedimented through a 0.5-ml 33%
sucrose cushion in PBS at 4°C at 90,000  g for 45 min in a Beckman benchtop
ultracentrifuge using a TLA55 rotor.
To determine the infectious titer of viral preparations made at the NPT, they
were treated with 1 g/ml trypsin for 30 min at room temperature to activate the
hemagglutinin (HA), and serial dilutions were used to infect MDCK cells. In-
fection was defined as NP expression visible by immunofluorescence at 4 h
postinfection (p.i.). The Poisson formula was used to calculate the MOI and
hence the infectious titer from wells showing 15 to 50% infection. The titers of
virus particles were determined by electron microscopy (EM) as previously
described (31).
To analyze virion morphology, a method modified from that of Bourmakina
and Garcia-Sastre (10) was used. Six milliliters of virus stock was diluted in
OptiMem to 10 ml and placed over a 3-ml 25% sucrose cushion in NTE buffer
(10 mM Tris, pH 7.6, 100 mM NaCl, 1 mM EDTA). The tubes were centrifuged
at 99,000  g for 1.5 h at 4°C using a Beckman-Coulter Optima LE-80K ultra-
centrifuge and an SW40Ti rotor. The pelleted virus was resuspended in 50 l
NTE buffer, mounted onto Formvar-coated grids, and negatively stained with
phosphotungstic acid. The grids were viewed and photographed using a Philips
CM100 transmission electron microscope. To analyze virion RNA content, RNA
extracted from virus particles first pelleted through a sucrose pad was analyzed
by urea-PAGE and silver staining as previously described (31).
RESULTS
Identification of the ts lesion in A/FPV/Rostock/34 US3. A
series of ts FPV mutants that mapped to segment 5 were
generated by mutagenesis with 5-fluorouracil in the 1970s (3,
4). Virtually no phenotypic characterization of these mutants
has been reported (40). Here, we have used more recent tech-
nologies to revisit them, further defining and characterizing the
US3 mutant to increase our understanding of the role of the
NP protein in the viral life cycle. Fresh stocks of WT and US3
FPV were prepared in eggs at the PT, and their plaque titers
were compared in CEF at the PT and NPT. Both viruses
showed a high titer at the PT, but while the titer of the WT
FPV was essentially the same at the NPT, that of the US3
mutant was 70-fold lower (Table 1), confirming its temperature
sensitivity. To identify the mutation(s) responsible for the ts
phenotype of US3, we isolated and sequenced three indepen-
dent clones of segment 5 from WT FPV and two clones from
US3. The resulting nucleotide sequences were translated and
TABLE 1. Plaque titer of viruses at PT and NPTa
Virus
Titer
PT/NPT ratio
PT NPT
WT FPV 1.5  108 1.0  108 1.5
US3 5.0  108 7.0  106 71
WT PR8 4.3  107 3.3  107 1.3
US3.5 5.5  107 3.8  105 145
US3.6 6.5  107 7  105 93
a Titers (in PFU/ml) were measured at 34°C (PT) and 39°C (NPT).
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compared to the database sequence for FPV NP (64). Both
clones of US3 showed a single amino acid change, M239L
(ATG 3 TTG), relative to the parental WT virus. Two other
amino acid changes were seen in all clones, both WT and US3,
relative to the published sequence: M200I (ATG3 ATC) and
P359S (CCC3 TCC). We infer that the last two changes were
insignificant in terms of a ts phenotype; it is likely they reflect
the differing passage histories of the various FPV strains. Con-
sistent with this, NP from the Giessen strain of A/Chicken/
Rostock/34 also has an isoleucine at position 200 and a serine
at position 359 but differs at two other amino acid positions
relative to the Cambridge and Institute for Animal Health
sequences (43).
The single unique change in the US3 NP sequence is con-
sistent with its assignment as a segment 5 mutant (4). To test
this, as well as to generate a virus in which the mutation could
be studied away from any epistatic changes elsewhere in the
FPV genome, reverse genetics was used to introduce the US3
point mutation into the PR8 strain of virus, which also encodes
a methionine at residue 239 of NP. Two independent stocks of
the PR8 US3 mutant, denoted US3.5 and US3.6, along with
virus (WT) rescued from cDNAs coding for the WT NP se-
quence, were generated from transfected 293T cells and fur-
ther amplified in MDCK cells. Plaque titers of the resulting
viruses were then measured at the PT and NPT in MDCK cells.
WT PR8 and both PR8 US3 viruses had similar titers at the
PT, indicating successful rescue of the viruses (Table 1). How-
ever, similar to the original FPVs but in contrast to WT PR8,
the PR8 US3 viruses showed a 100-fold drop in titer at the
NPT (Table 1), indicating a replication defect at higher tem-
peratures. The PR8 US3 plaques that were seen at the NPT
were smaller than those of the WT virus (data not shown).
Similar-magnitude ts replication defects were seen in second-
passage US3 virus stocks used for subsequent experiments
(data not shown). Thus, the M239L mutation is sufficient to
induce a ts phenotype in the heterologous genetic background
of PR8, further confirming its identity as the US3 ts lesion.
The US3 lesion does not affect viral-gene expression or RNA
synthesis. As an initial characterization, the abilities of the
US3 mutants to perform the early functions of viral-gene ex-
pression and RNA synthesis were tested. First, we employed a
system in which viral RNPs were reconstituted in cells by
plasmid transfection and their abilities to transcribe and ex-
press a synthetic segment encoding CAT were measured (50).
When RNPs were reconstituted with all components derived
from PR8 virus and supplied with a vRNA template, large
amounts of CAT were expressed in cells incubated at 39°C
(Fig. 1A), indicating efficient transcription of the segment.
When PR8 NP was replaced by WT FPV NP, reduced, but still
substantial, amounts of CAT were made, perhaps reflecting
some incompatibility between the mammalian- and avian-vi-
rus-derived RNP polypeptides. However, no further reduction
in CAT synthesis resulted from use of the FPV US3 NP (Fig.
1A). Theoretically, at least, the assay described above does not
require genome replication, as the input vRNA molecules can
be directly transcribed to mRNA. We therefore tested the
effects of supplying a cRNA polarity segment, thus introducing
a requirement for vRNA synthesis in order to achieve CAT
expression. Effectively identical results were obtained, and the
FPV US3 NP showed no obvious defect in CAT gene expres-
sion at the NPT (Fig. 1B). Next, we tested the PR8 US3
mutants in the same system. Again, no defect in viral-gene
expression relative to the activity of the counterpart WT
polypeptide was seen at either the PT or NPT (Fig. 1C), al-
though as expected (17), increased levels of reporter gene
expression were seen at the higher temperature. We conclude
that the US3 mutation does not affect viral-gene expression at
the NPT in recombinant reporter assays.
To examine the effect of the US3 mutation on virus gene
expression during infection of cultured cells, MDCK cells were
infected with the engineered PR8 viruses and pulse-labeled
with [35S]methionine for periods ending at 4.5 and 8 h p.i. The
expected pattern of viral-protein synthesis was seen for all
viruses at the PT, with early synthesis of NP and NS1 and later
synthesis of M1 and HA (Fig. 2A, lanes 3 to 8). At the NPT, a
similar outcome was obtained, with all viruses synthesizing
comparable amounts of HA, NP, M1, NS1, and NS2 polypep-
tides (lanes 11 to 16). Essentially identical results were ob-
tained when CEF were infected with the parental WT and US3
FPV viruses; no ts defect in virus gene expression was observed
(data not shown). The accumulation of selected viral proteins
during infection with the PR8 viruses was also monitored.
Western blots were probed for early NP and PB2 and late M1
and M2 viral proteins. All viruses showed similar levels of
protein accumulation in samples from cells incubated at the
PT, with abundant synthesis apparent by 8 h p.i. (Fig. 2B). At
the NPT, NP, PB2, and M1 proteins were detected in WT virus
infection at 4.5 h p.i., and their levels increased by 8 h p.i.,
whereas M2 was detected in significant amounts only at 8 h p.i.
(Fig. 2B, lanes 3 and 4). Both US3 viruses displayed essentially
the same pattern of protein expression as WT PR8 (lanes 5 to
8). Thus, the US3 ts viruses mediate normal levels of viral-
protein expression at both the PT and NPT.
Many data indicate a role for NP in viral-genome replication
(reviewed in reference 23). Although mini-genome assays in-
dicated that US3 NP was capable of mediating the transcrip-
tion and replication of a synthetic cRNA or vRNA (Fig. 1), it
was important to test whether this held true during an actual
infection. MDCK cells were infected with the PR8 viruses at
FIG. 1. Abilities of WT and mutant NP polypeptides to support
viral-gene expression. Influenza virus RNPs were reconstituted in 293T
cells by transfection of expression plasmids for PR8 PB1, PB2, PA, and
the indicated NP polypeptides (A and B) or WT PR8 NP or either of
two clones (US3.5 and US3.6) of PR8 NP bearing the US3 mutation
(C), along with plasmids expressing a synthetic vRNA (vCAT) or
cRNA (cCAT) molecule encoding CAT. The means (plus range [A
and B] or standard error [C]) accumulation of CAT polypeptide from
two (A or B) or three (C) independent experiments are plotted.
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the NPT, after which total cellular RNA was extracted at 6 and
12 h p.i. and analyzed for segment 2, 5, and 7 vRNA content by
primer extension. vRNA species were not observed in mock-
infected samples for any of the three segments investigated
(Fig. 3, lanes 3 and 4). However, WT, US3.5, and US3.6 viruses
all showed similar levels of vRNA synthesis at both time points
for all segments analyzed (lanes 1, 2, and 5 to 8). Similar
outcomes were observed for genome synthesis at the PT and in
replicate independent experiments (data not shown). Overall,
at the NPT, the US3 mutant was found to mediate apparently
WT patterns of genome expression and replication. Thus, the
US3 viruses appear to have ts defects that operate after vRNA
synthesis, potentially during viral maturation.
Analyses of NP subcellular localization during infection.
Next, transport of the ts NP mutant RNPs from the nucleus to
sites of virion assembly (the apical plasma membrane) was
examined by immunofluorescence. Infected MDCK cells cul-
tured at the NPT were stained for NP as a marker for RNP and
cellular Lap-2 to delineate the nucleus. At 4.5 h p.i., both WT
and US3 NP proteins were found to be largely nuclear in some
cells and cytoplasmic in others (Fig. 4A), as expected for an
intermediate time point in the virus life cycle (22). By 8 h p.i.,
the majority of WT and US3 NP was observed in the cyto-
plasm, where it concentrated at the apical cell periphery in
many of the infected cell clumps. To reduce the subjective
nature of immunofluorescence, the subcellular localization of
NP in cells during time course infections with the WT and the
ts mutant was scored according to whether the fluorescence
was predominantly nuclear or cytoplasmic (Fig. 4B). For both
WT and US3 viruses, the percentage of infected cells exhibit-
ing nuclear NP decreased with time, suggesting that WT and
mutant RNPs were progressively exported to the cytoplasm as
infection proceeded. A slight delay was observed for the US3
virus in comparison to the WT, but the majority of cells con-
tained cytoplasmic NP at 8 h p.i. This suggested that the nu-
clear export of RNPs in US3-infected cells at the NPT was
normal.
After nuclear export, RNPs traffic to the apical plasma mem-
brane to be assembled into virus particles (13). A biochemical
test was undertaken to investigate the association of the mu-
tant NP molecules with cell membranes. MDCK cells were
infected at the NPT for 8 h, and nuclear and cytoplasmic
fractions were isolated. The cytoplasmic fraction was subjected
to a flotation assay to separate soluble and membrane-associ-
ated proteins. Fractions of the gradients were harvested and
analyzed by Western blotting for NP, HA, and M1. In samples
derived from cells infected with WT virus, HA and M1 clearly
partitioned to low-buoyant-density membrane-associated frac-
tions, in agreement with previously published data (2, 13, 70)
(Fig. 5). WT NP was distributed throughout the gradient in
both nonbuoyant and membrane-associated fractions, which
also agreed with previous studies (2, 13, 70). Similar results
were seen for the PR8 US3 virus, in which HA and M1 parti-
tioned to the membrane-associated fractions and the ts NP
mutant proteins were found in both buoyant and nonbuoyant
fractions. In addition, no change in the fraction of membrane-
associated NP was seen between the WT and the US3 mutant
when the flotation experiments were repeated at 4°C in the
presence of Triton X-100 to analyze lipid rafts (data not
FIG. 2. Viral-protein expression in WT and US3 mutant virus-infected cells. MDCK cells were infected or mock infected at an MOI of 5 with
the indicated viruses and incubated at either 34°C (PT) or 39°C (NPT) for 4.5 or 8 h. Two hours prior to being harvested, the cells were labeled
with [35S]methionine. The polypeptides were separated by SDS-PAGE, and the radiolabeled proteins were detected by autoradiography (A) or by
Western blotting (B) for the indicated antigens. Major viral and cellular polypeptides are labeled.
FIG. 3. vRNA synthesis during WT and US3 virus infection. Total
RNA was extracted 6 or 12 h p.i. from MDCK cells infected at an MOI
of 0.5 or mock infected and incubated at the NPT. Segment 2, 5, and
7 vRNA accumulation (as labeled) was monitored by radiolabeled-
primer extension, urea-PAGE, and autoradiography.
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shown). Thus, the US3 mutant is capable of interacting nor-
mally with cellular membranes at the NPT in the context of a
viral infection.
The US3 mutant has a defect in virion assembly. The ability
of the US3 mutant to generate viral particles at the NPT during
an infection was examined next. To generate virus preparations
at the NPT with minimal contamination from input material
prepared at the PT, MDCK cells were infected at the NPT,
acid treated to remove residual inoculum, and then incubated
for a further 4 h or 24 h at the NPT. The supernatants were
first assessed for virion content by Western blotting with anti-
PR8 virus sera after the virus particles were pelleted through a
sucrose cushion to remove contaminating cellular debris. No
viral proteins were detected in supernatants harvested from
mock-infected cells (Fig. 6, lane 1) or from infected cells at 4 h
p.i. (lane 8), indicating successful removal of input virus made
at the PT. The major structural viral proteins were detected in
positive controls, where either 106 or 107 PFU of egg-grown
stocks of c-PR8 virus were pelleted (lanes 2 to 4). Similarly,
HA, NP, and M1 proteins were detected in comparable
amounts in WT and mutant virus preparations harvested at
24 h p.i. (lanes 5 to 7). This suggested that the WT and US3
viruses produce similar numbers of virus particles in a one-step
replication cycle. To further characterize virion production by
US3, particle counts were performed using EM. Two indepen-
dent engineered WT virus stocks made at the NPT contained
around 3  109 particles/ml, while three preparations of the
US3 viruses contained somewhat higher number of virions,
with around 2  1010 particles/ml (Table 2). Thus, the US3
mutation does not block the assembly or release of virus par-
ticles at the NPT.
The US3 viruses consistently replicated to around 100-fold-
lower titers under multicycle growth conditions at the NPT
(Table 1) and yet produced slightly higher numbers of particles
in a single round of infection (Table 2). Therefore, the viability
FIG. 4. Subcellular localization of WT and US3 NP. MDCK cells
were infected (or mock infected) at an MOI of 5 and incubated at the
NPT for the indicated times. The cells were then fixed, and NP (green)
and Lap-2 (red) proteins were stained using the appropriate antibodies
before being viewed by fluorescence microscopy. (A) Representative
images. (B) The subcellular localization of NP in 100 to 200 infected
cells was scored as predominantly nuclear or cytoplasmic. The mean
(plus range) percentages of infected cells observed to have nuclear NP
are indicated for the various time points.
FIG. 5. Association of WT and ts NP with cellular membranes. Cell
lysates isolated from infected MDCK cells (MOI  10) after 8 h of
incubation at the NPT were subjected to flotation assay, and the
resulting gradient fractions (P, pellet) were analyzed by Western blot-
ting for NP and HA (top) and M1 (bottom). Low-buoyant-density
fractions were defined as fractions 6 to 9.
FIG. 6. Analysis of virus particles released at the NPT. Equal vol-
umes of medium from MDCK cells infected or mock infected at an
MOI of 2 with the indicated viruses and incubated for 24 h (or, in one
case, 4 h) at the NPT were sedimented through a sucrose cushion, and
the pellet was analyzed by Western blotting with anti-PR8 serum.
Known concentrations of egg-grown Cambridge A/PR/8/34 (c-PR8)
virus were similarly processed. Viral polypeptides are indicated on the
right.
566 NOTON ET AL. J. VIROL.
of the single-cycle virion preparations was investigated by
plaque assay. The titers of the WT virus stock were determined
to be around 108 PFU/ml, giving an average particle/PFU ratio
of 23 (individual values are shown in Table 2). This is in good
agreement with previously published estimates for influenza A
virus (20, 45, 60). The titers of the US3 virus preparations were
consistently around 10-fold lower (107 PFU/ml), despite
their higher particle counts, giving an average particle/PFU
ratio of 1,150 (individual values are shown in Table 2). Thus,
the US3 mutation results in the production of virus particles
with significantly reduced infectivity compared to WT virus.
The mutant virus generated large numbers of defective par-
ticles unable to initiate the multicycle replication needed to
form a plaque. This could reflect particles unable to infect cells
and/or particles that were infectious but that initiated abortive
infections. The latter possibility could plausibly result from
infection with virions that did not contain all eight viral seg-
ments (31). To examine these possibilities, we first titrated the
ability of the NPT viral preparations to establish viral-gene
expression in single cells (assayed by immunofluorescence of
NP). Therefore, by comparing the titer as calculated from the
number of NP-positive cells with the titer as measured by
plaque assay, an indication of the number of infectious virions
could be gained. In addition, we reasoned that the absence of
segment 4, 6, 7, or 8 would not affect the establishment of NP
expression but would prevent the multicycle growth needed to
form a plaque (31, 44). Therefore, comparing the titer as
calculated from the number of NP-positive cells with the titer
as measured by plaque assay would be informative regarding
the infectivity of the virus stocks and might provide indirect
evidence as to their genome contents. MDCK cells were in-
fected at the NPT with serial dilutions of WT and US3 PR8
viruses. At 4 h p.i., the cells were assessed for infection by
immunofluorescent staining for NP, and the percentage of
infected cells was determined. Dilutions in which 15 to 50%
of cells were infected were used to calculate the MOI via the
Poisson formula and hence the titer of the viral stock in terms
of infectivity/ml. This varied from 108 infectious particles/ml
for WT virus to107 infectious particles/ml for US3 (Table 2).
Comparison of these values with the matching particle count
data for the virus preparations indicated that, again, the US3
virus had a drastically reduced specific infectivity (particle/
infectivity ratio) (Table 2). The magnitudes of the defects in
the particle/infectivity ratios were similar to those seen for the
particle/PFU ratio, and when the PFU/infectivity ratios were
considered, they fluctuated around 1:1 for both WT and US3
viruses (Table 2). These results do not support the hypothesis
that US3 virions made at the NPT lack a complete set of
genome segments and instead suggest that the majority are
noninfectious.
As a direct test of the vRNA contents of the particles, RNA
was extracted from equal numbers of WT and US3 viral par-
ticles made at the NPT, as well as egg-grown c-PR8 virus as a
positive control. Samples were separated by urea-PAGE and
silver stained to visualize the viral segments. However, despite
the US3 viruses having a particle/PFU ratio more than 50-fold
lower than that of the WT virus (Table 2), all eight vRNA
segments were detected in approximately similar amounts for
all viruses examined (Fig. 7, compare lanes 2 to 4). Thus, the
US3 mutant viruses are not defective due to an inability to
package the viral genome at the NPT.
Having established that the US3 virus generates large num-
bers of poorly infectious particles that nevertheless have an
apparently normal genome content, the morphology of the
particles generated at the NPT was examined by EM (Fig. 8).
WT virions were seen to be the expected pleomorphic spheres
with a diameter of approximately 100 nm (34, 57). However,
US3 virions consisted of a mixture of normal-appearing parti-
cles and elongated, distended virions approximately 300 nm in
length. Approximately 1% of WT particles displayed the ex-
tended, irregular particle shape, whereas between 15 and 30%
of the virions of US3 mutants had abnormal morphology. Fur-
thermore, a high proportion (on average, 65% of two indepen-
dent preparations) of the US3 virions were partially disrupted,
with what appeared to be leakage of internal components (Fig.
8). In contrast, US3 virions formed at the PT appeared mor-
phologically normal and were indistinguishable from those of
the WT virus (Fig. 8). This suggests that US3 has a ts defect at
the level of virus assembly.
Defective virion assembly presumably results from altered
protein-protein interactions mediated by the US3 NP. The
TABLE 2. Particle and infectivity titers of viral stocks made at the NPT
Virus Expt No. of particles/ml PFU/ml Infectivity/ml Particle/PFU ratio Particle/infectivityratio
PFU/infectivity
ratio
WT 1 2.5  109 3  108 1.6  108 8 16 1:9
WT 2 3.7  109 1  108 9.4  107 37 39 1:1
US3.5 1 2  1010 4  107 3.6  107 500 556 1:1
US3.5 2 1  1010 6.8  106 2.3  107 1,481 444 0:3
US3.6 2 2.5  1010 1.7  107 7.8  106 1,471 3,205 2:2
FIG. 7. vRNA contents of viral particles made at the NPT. RNA
was isolated from equal numbers of WT, US3, and c-PR8 virus parti-
cles made at the NPT, separated by urea-PAGE, and detected by silver
staining. RNA extracted from egg-grown c-PR8 virus was used as a
marker. Segment numbers are indicated on the left.
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simplest hypothesis is that the mutation affects NP-M1 inter-
actions. A previous study correlated the strength of the inter-
action between M1 and RNPs with the morphology of virus
particles, postulating a weaker association in filamentous viri-
ons (38). We therefore tested the effects of varying segment 7
sequences on the growth of viruses with WT and US3 NP genes
in an otherwise PR8 genetic background. Swapping the PR8
segment 7 with that of nonfilamentous WSN virus resulted in
viruses that were easily rescuable and grew well at the PT, with
either WT or US3 NP (Table 3). The US3 PR8-WSN chimeric
viruses were also ts, as expected (data not shown). However,
when segment 7 from the filamentous Udorn virus was used,
only a virus with WT NP could be efficiently rescued. Multiple
independent attempts with the US3 NP gene resulted in the
recovery of infectious virus on only one occasion, and it was at
very low titer and unable to form clear plaques (Table 3). To
investigate whether this resulted from an incompatibility be-
tween the US3 NP and Udorn M1 or M2, we tested a chimeric
segment 7 containing WSN M2 but Udorn M1 (21). This seg-
ment was also readily rescued into a viable virus with the WT
PR8 NP gene, but again, very poorly with the US3 mutant
(Table 3). Thus, the US3 NP is almost totally incompatible
with the M1 gene from a filamentous virus even at the PT,
providing genetic evidence that the M239L mutation alters the
interaction of NP with M1.
DISCUSSION
Most NP ts mutants that have been previously characterized
show defects in vRNA synthesis at the NPT (35, 40, 43, 48, 61,
63). However, although there are abundant data showing that
NP plays a key role as a structural and functional component
of viral RNPs, it is also likely to be important at later time
points in the replication cycle. Its ability to associate with M1
and a number of cellular proteins, including CRM1 and actin,
as well as with lipid rafts, has been proposed to be involved in
posttranscriptional steps, such as RNP trafficking and/or virus
assembly. Here, we show that NP also plays an important role
in the assembly of infectious viral particles. The M239L change
identified in FPV US3 conferred a ts reduction in the growth
titer of around 100-fold when introduced into the NP of PR8
virus, despite being a relatively conservative change to an
amino acid not especially well conserved in influenza viruses
(approximately a quarter of natural isolates contain valine at
position 239 [26]). The recently solved crystal structure of the
A/Hong Kong/483/97 (H5N1) NP (51) shows that the side
chain of M239 is buried in the interior of the helical bundle
(helices 8 to 11) that comprises the major element of the head
domain of the protein (Fig. 9). Although valine is accommo-
dated in this position in the A/WSN/33 NP (68), replacement
with leucine is likely to destabilize the region because of al-
tered interactions with amino acids in helices 9 and 11. How-
ever, although helices 8 and 9 form one face of the arginine-
rich cleft that likely forms the RNA-binding site (24, 51, 68),
we found no evidence that the ts defect operated at any stage
of vRNA synthesis or protein expression, strongly suggesting
that the mutation does not affect RNA binding by NP. Two
other NP ts mutants (ts56 and ts81) that have been shown to
have defects in RNA synthesis and RNA binding at the NPT
(48, 59, 61) both have lesions within the body domain of NP
(Fig. 9). We also did not find any significant defect in nuclear
export of the US3 NP, unlike another FPV ts mutant (ts19)
proposed to have a defect that operates after RNA synthesis
FIG. 8. EM Analysis of WT and US3 influenza virus morphology. Viral particles generated at the NPT were concentrated by pelleting virions
through a sucrose cushion, mounted onto Formvar-coated grids, stained with phosphotungstic acid, and imaged by EM. The arrows indicate
apparent disruption of particles.
TABLE 3. Influence of segment 7 on growth of viruses at the PTa
Segment 7 Segment 5 Successb Titer at PTc
WSN WT 3/3 2.3  107
US3 4/4 1.3  108
Udorn WT 3/3 2.3  107
US3 1/6 25d
Ud M1/WSN M2 WT 2/2 1.3  107
US3 1/6 1.5  103d
a Titers (in PFU/ml) were measured at 34°C (PT).
b Number of times viable virus was recovered/number of independent trans-
fections.
c Average titer from the number of rescues shown in the Success column.
d Titers are an estimate of areas of cytopathic effect, as clear plaques were not
visible.
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(42, 59). Indeed, trafficking of NP to the plasma membrane was
apparently normal, as was genome packaging. Particle forma-
tion by the mutant, at least when it was assessed numerically,
was reproducibly slightly higher (on average, nearly sixfold)
than that of the WT virus. However, despite their apparently
normal biochemical composition, the specific infectivity of US3
particles made at the NPT was 100-fold lower than that of WT
virus. Consistent with this, the majority of US3 particles made
at the NPT (but not at the PT) showed morphological abnor-
malities, either in the form of excessively pleomorphic shapes
or, more often, apparent protrusion of material from the virion
interior beyond the glycoprotein fringe. We thus conclude that
the NP US3 ts mutation affects virion assembly and/or stability,
indicating a new role for NP in virion morphogenesis. Analysis
of the viability of a set of segment 7 reassortants suggested that
the M239L mutation affects the interaction of NP with M1,
suggesting a molecular explanation for the virion assembly
defect. Although the ts mutation is located on the interior of
the polypeptide, we note that the the ts lesion in FPV ts19,
which leads to defects in NP nuclear export and thus may also
affect interactions with M1 (42), lies on helix 6 on the opposite
face of the head domain (Fig. 9). It is therefore tempting to
speculate that the head domain of NP interacts with M1.
Our data do not distinguish between the ts mutation in US3
NP causing defects in particle formation and/or (perhaps as a
consequence of the former) stability. The mechanism by which
the membrane of influenza virions is pinched off from the
plasma membrane is currently uncertain (14), and the pro-
lapsed appearance of US3 virions formed at the NPT could
conceivably reflect a defect in this process. However, similar
malformations have been induced in previously normal prep-
arations of WT virions by protease digestion (60), perhaps
favoring the hypothesis that here, the ts defect somehow ren-
ders virions more fragile and susceptible to mechanical or
biochemical disruption. However, we have been unable to
demonstrate increased susceptibility of US3 virions to either
thermal denaturation or freeze-thaw cycles (data not shown).
Nevertheless, we do not consider that these negative findings
disprove the hypothesis because previous biochemical analyses
of NP ts mutants have shown that (at least when the function
of RNA binding is considered) protein synthesized at the PT
retains its activity at the NPT (24, 48). It is also possible that
the freeze-thaw and thermal-denaturation assays we employed
to test particle stability predominantly measure conforma-
tional changes in HA and that any function of NP in lending
stability to particles is more subtle.
Irregularly shaped virions have previously been associated
with the loss of the cytoplasmic tails of HA and NA and
mutations in M1 (12, 34, 38). The phenotypic similarity of the
NP mutant described here is interesting and could indicate a
role for NP alongside the glycoproteins and M1 in determining
viral morphology. However, the similarity in appearance of the
virions alone cannot distinguish between putative roles for NP
in morphology and/or stability. In addition to their established
influences on particle shape, HA and M1 have been proposed
to be the principal viral proteins required for influenza virus
budding (16, 27, 36).
If the US3 mutation affects particle assembly and/or stabil-
ity, it probably does so by altering protein-protein interactions
in the virion. Until the mechanism of influenza virus budding is
better understood, an interaction with a cellular protein cannot
be ruled out. However, the simplest explanation, supported by
the evident incompatibility between the M239L change and
M1 from Udorn virus, is that the US3 mutation alters the
interaction of RNPs with M1. We did not detect any difference
in the binding of WT and US3 NP (synthesized and tested at
the NPT) to PR8 M1 using an in vitro assay system we recently
established (reference 52 and data not shown). However, this
does not rule out more subtle differences in vivo or with an M1
protein from a filamentous strain of influenza virus. However,
although there is a wealth of biochemical data supporting an
NP-M1 interaction and the significance of this for RNP nuclear
export is well established (9), evidence to support a role for it
in virion assembly is surprisingly sparse. Indeed, the role of M1
in budding itself has been questioned (16), and two recent
studies have identified populations of virions that apparently
lack an M1 tegument (28, 66). It is also interesting that muta-
tion of the basic sequence in M1 proposed as an RNP inter-
action site leads to reduced levels of M1, but not NP, in virus
particles (39). Further experiments to elucidate the nature and
function of the NP-M1 interaction during virus assembly would
be worthwhile.
The cytoplasmic tails of the viral membrane proteins are also
reasonable candidates for providing interactions with RNPs
during virion assembly. A number of recent studies have sug-
gested a role for M2 in packaging of RNPs into virus particles
(15, 32, 33, 46, 47), so a defective NP-M2 interaction is possi-
ble. So far, no direct interaction of the two proteins has been
demonstrated, although Bron et al. (11) found that M2 cosedi-
mented with RNPs and M1 from lysed virions. However, M2
mutants with truncations in the cytoplasmic tail produce viri-
ons with a reduced NP and vRNA content, which would be
FIG. 9. Locations of ts mutations in the NP structure. The side
chain of M239 (US3) (this study) is depicted as dark-green spheres
against the secondary-structure elements (helices, pink; -sheet, yel-
low; coil, gray lines) of the A/Hong Kong/483/97 NP (Protein Data
Bank file 2Q06, chain B) (51). The side chain of R162 (ts19; another
late-acting NP ts mutation) (42) is indicated in light green, while the
side chains of S314 and A332 (ts56 and ts81, respectively, both of which
affect RNA synthesis and lead to ts RNA-binding activity) (48) are
colored light and dark blue, respectively. The head and body domains
of NP are also indicated, as are helices 6 and 8 to 11 of the head
domain and the prominent cleft that likely forms the RNA-binding
site.
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inconsistent with the normal vRNA packaging seen here with
US3 NP. A direct interaction between RNPs and the cytoplas-
mic tail of HA and/or NA is also a possibility, as seen in a
member of the Bunyaviridae (54). Similar to M2 truncations,
however, viruses with deletions in the HA and NA cytoplasmic
tails package reduced amounts of genome (71), rather than the
normal amounts of vRNA seen here.
It is likely that RNPs participate in multiple interactions with
other virion components and that these interactions need to be
looked at in combination to elucidate the precise role of the
mutation described here in decreasing virion viability. The
interactions between RNPs and other structural proteins pos-
sibly include a degree of redundancy, as has been seen with the
cytoplasmic tails of HA and NA (34). Further analysis of the
molecular defect exhibited by the US3 NP will help elucidate
the process of influenza virion assembly.
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